202 related articles for article (PubMed ID: 34728525)
21. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Kaley TJ; Panageas KS; Mellinghoff IK; Nolan C; Gavrilovic IT; DeAngelis LM; Abrey LE; Holland EC; Lassman AB
J Neurooncol; 2019 Sep; 144(2):403-407. PubMed ID: 31325145
[TBL] [Abstract][Full Text] [Related]
22. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
23. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
[TBL] [Abstract][Full Text] [Related]
25. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I; Pérez-Fidalgo JA; Hamilton EP; Valabrega G; Van Gorp T; Sehouli J; Cibula D; Levy T; Welch S; Richardson DL; Guerra EM; Scambia G; Henry S; Wimberger P; Miller DS; Klat J; Martínez-Garcia J; Raspagliesi F; Pothuri B; Romero I; Bergamini A; Slomovitz B; Schochter F; Høgdall E; Fariñas-Madrid L; Monk BJ; Michel D; Kauffman MG; Shacham S; Mirza MR; Makker V;
J Clin Oncol; 2023 Dec; 41(35):5400-5410. PubMed ID: 37669480
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
Phuphanich S; Raizer J; Chamberlain M; Canelos P; Narwal R; Hong S; Miday R; Nade M; Laubscher K
J Neurooncol; 2017 Jan; 131(1):185-191. PubMed ID: 27844311
[TBL] [Abstract][Full Text] [Related]
28. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
[TBL] [Abstract][Full Text] [Related]
29. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
30. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
31. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
32. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D; Berdeja JG; Reece D; White D; Lentzsch S; Gasparetto C; Huff CA; Jagannath S; Baz R; Nooka AK; Richter J; Abonour R; Parker TL; Yee AJ; Moreau P; Lonial S; Tuchman S; Weisel KC; Mohty M; Choquet S; Unger TJ; Li K; Chai Y; Li L; Shah J; Shacham S; Kauffman MG; Dimopoulos MA
Leukemia; 2020 Sep; 34(9):2430-2440. PubMed ID: 32094461
[TBL] [Abstract][Full Text] [Related]
33. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
[TBL] [Abstract][Full Text] [Related]
35. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
[TBL] [Abstract][Full Text] [Related]
36. Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Nilsson S; Stein A; Rolfo C; Kranich AL; Mann J; Papadimitriou K; Theile S; Amberg S; Bokemeyer C
Curr Cancer Drug Targets; 2020; 20(10):811-817. PubMed ID: 32598257
[TBL] [Abstract][Full Text] [Related]
37. The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
39. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM; Razak AA; Somaiah N; Chawla S; Martin-Broto J; Grignani G; Schuetze SM; Vincenzi B; Wagner AJ; Chmielowski B; Jones RL; Riedel RF; Stacchiotti S; Loggers ET; Ganjoo KN; Le Cesne A; Italiano A; Garcia Del Muro X; Burgess M; Piperno-Neumann S; Ryan C; Mulcahy MF; Forscher C; Penel N; Okuno S; Elias A; Hartner L; Philip T; Alcindor T; Kasper B; Reichardt P; Lapeire L; Blay JY; Chevreau C; Valverde Morales CM; Schwartz GK; Chen JL; Deshpande H; Davis EJ; Nicholas G; Gröschel S; Hatcher H; Duffaud F; Herráez AC; Beveridge RD; Badalamenti G; Eriksson M; Meyer C; von Mehren M; Van Tine BA; Götze K; Mazzeo F; Yakobson A; Zick A; Lee A; Gonzalez AE; Napolitano A; Dickson MA; Michel D; Meng C; Li L; Liu J; Ben-Shahar O; Van Domelen DR; Walker CJ; Chang H; Landesman Y; Shah JJ; Shacham S; Kauffman MG; Attia S
J Clin Oncol; 2022 Aug; 40(22):2479-2490. PubMed ID: 35394800
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E
J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
